AbbVie pays Gubra $350m upfront to enter obesity field
GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to AbbVie. Amylin is a hormone that gives a feeling of fullness in the brain that suppresses appetite, reduces food intake, and delays gastric emptying.
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...
3d
AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback